Application of the Dapagliflozin Heart Failure Indication to Clinical Practice

2021 
Dr Bryan Wasson from the University of Texas Southwestern Medical Center, Dallas, TX; and Bridlewood Family Healthcare, Flower Mound, TX, moderated the topic "Application of the Dapagliflozin Heart Failure Indication to Clinical Practice" with Dr Javed Butler from the Department of Medicine, University of Mississippi, Jackson, MS, and Dr Michael Shanik from the Department of Medicine, Stony Brook University Hospital, Stony Brook, NY; and Endocrine Associates of Long Island, Smithtown, NY, participating. The discussion focused primarily on: 1. Cardiovascular disease reduction trials and heart failure reduction trials in patients with type 2 diabetes; 2. comparisons between the DECLARE-TIMI 58 CV outcomes trial, the EMPA-REG trial, and the DAPA-HF clinical trial; 3. the results and clinical implications of the DECLARE-TIMI 58 CV outcomes trial; 4. the Food and Drug Administration–approved indication for dapagliflozin for heart failure hospitalization reduction; and 5. the application of the new dapagliflozin heart failure with diabetes data to clinical practice. [Published online ahead of print 2020 August] (Med Roundtable Cardiovasc Ed. 2020 August) ©2020 FoxP2Media, LLC This roundtable was supported by AstraZeneca. The discussants (authors) developed the discussion and reviewed the transcript for important intellectual content, and approved the final version for publication. The authors maintained control of the discussion and the resulting content of this article.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []